[go: up one dir, main page]

CO2022001094A2 - Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas - Google Patents

Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas

Info

Publication number
CO2022001094A2
CO2022001094A2 CONC2022/0001094A CO2022001094A CO2022001094A2 CO 2022001094 A2 CO2022001094 A2 CO 2022001094A2 CO 2022001094 A CO2022001094 A CO 2022001094A CO 2022001094 A2 CO2022001094 A2 CO 2022001094A2
Authority
CO
Colombia
Prior art keywords
pyrazines
pyrrolo
disclosed
hpk1 inhibitors
hpk1
Prior art date
Application number
CONC2022/0001094A
Other languages
English (en)
Inventor
Jing Li
Zhiwei Wang
Sanjia Xu
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CO2022001094A2 publication Critical patent/CO2022001094A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En el presente documento se divulga un compuesto de Fórmula (I), o un estereoisómero del mismo, o una sal farmacéuticamente aceptable del mismo, y composiciones farmacéuticas que lo comprenden. También se divulga un método para tratar trastornos o enfermedades relacionados con HPK1 utilizando el compuesto divulgado en el presente documento.
CONC2022/0001094A 2019-07-04 2022-02-02 Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas CO2022001094A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019094749 2019-07-04
CN2019123268 2019-12-05
CN2020089498 2020-05-09
PCT/CN2020/100037 WO2021000925A1 (en) 2019-07-04 2020-07-03 PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Publications (1)

Publication Number Publication Date
CO2022001094A2 true CO2022001094A2 (es) 2022-04-29

Family

ID=74100904

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001094A CO2022001094A2 (es) 2019-07-04 2022-02-02 Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas

Country Status (14)

Country Link
US (1) US12454534B2 (es)
EP (1) EP3994136A4 (es)
JP (1) JP7579816B2 (es)
KR (1) KR20220029690A (es)
CN (3) CN115073474B (es)
AU (1) AU2020299892A1 (es)
BR (1) BR112022000019A2 (es)
CA (1) CA3145751A1 (es)
CO (1) CO2022001094A2 (es)
IL (1) IL289553A (es)
MX (1) MX2022000244A (es)
TW (1) TWI848141B (es)
WO (1) WO2021000925A1 (es)
ZA (1) ZA202110732B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
PL3873903T3 (pl) 2018-10-31 2024-05-20 Gilead Sciences, Inc. Podstawione związki 6-azabenzimidazolu jako inhibitory hpk1
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
CN112239473B (zh) 2019-07-17 2023-12-08 百济神州(北京)生物科技有限公司 作为hpk1抑制剂的三环化合物的制备方法
CN114685490B (zh) * 2020-12-31 2025-03-28 南京再明医药有限公司 吡咯并吡啶类化合物及其应用
WO2022184152A1 (zh) * 2021-03-03 2022-09-09 劲方医药科技(上海)有限公司 稠环取代的六元杂环化合物及其制法和用途
CN115073472A (zh) * 2021-03-16 2022-09-20 江苏恒瑞医药股份有限公司 稠合二环类化合物、其制备方法及其在医药上的应用
WO2022199676A1 (zh) * 2021-03-26 2022-09-29 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
JP2024521706A (ja) * 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物
TW202313603A (zh) * 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl抑制劑化合物
TW202321239A (zh) 2021-07-20 2023-06-01 瑞典商阿斯特捷利康公司 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
JP2024528722A (ja) * 2021-07-30 2024-07-30 ベイジーン リミテッド ＨＰＫ１分解誘導薬としてのピロロ［２，３－ｂ］ピラジン系の二官能性化合物及びその使用
WO2023151559A1 (zh) * 2022-02-08 2023-08-17 和径医药科技（上海）有限公司 杂环化合物、包含其的药物组合物及其抗肿瘤应用
CN116731029A (zh) * 2022-03-11 2023-09-12 石药集团中奇制药技术（石家庄）有限公司 一类并环化合物及其制备和应用
WO2023207894A1 (en) * 2022-04-24 2023-11-02 Beigene , Ltd. POLYMORPH FORMS OF A 5H-PYRROLO [2, 3-b] PYRAZINE DERIVATIVE, METHODS OF PREPARATION, AND USES THEREFORE
CN116925082A (zh) * 2022-04-24 2023-10-24 百济神州(苏州)生物科技有限公司 5H-吡咯并[2,3-b]吡嗪衍生物的多晶型形式，制备方法及其用途
WO2023207911A1 (zh) * 2022-04-24 2023-11-02 上海医药集团股份有限公司 一种双环杂环化合物、药物组合物和应用
AR129722A1 (es) 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
AU2005269387A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
MX2007001127A (es) 2004-07-27 2007-07-11 Sgx Pharmaceuticals Inc Moduladores de pirrolo-piridina cinasa.
CN101098872B (zh) 2004-11-22 2012-09-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2010049173A1 (en) 2008-10-31 2010-05-06 Cenix Bioscience Gmbh Use of inhibitors of host kinases for the treatment of infectious diseases
NZ603644A (en) 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
CN101851237B (zh) 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
JP2012012332A (ja) 2010-06-30 2012-01-19 Dainippon Sumitomo Pharma Co Ltd 新規アザインドール誘導体
US9353107B2 (en) 2012-07-03 2016-05-31 Aurigene Discovery Technologies Limited 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors
EP2925319B1 (en) 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2016000615A1 (en) 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
KR101660863B1 (ko) 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
WO2016164641A1 (en) * 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG10202105964RA (en) 2015-06-25 2021-07-29 Univ Health Network Hpk1 inhibitors and methods of using same
CN106336413B (zh) * 2015-07-09 2021-04-20 广东东阳光药业有限公司 作为jak抑制剂的化合物及其用途
CN106432246B (zh) 2015-08-05 2020-07-07 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
US20180072741A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
MA46191A (fr) 2016-09-09 2021-04-21 Incyte Corp Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
US20180072718A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP3596075B1 (en) 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles as inhibitors of hpk1
EP3600292A4 (en) 2017-03-30 2021-04-07 Corvus Pharmaceuticals, Inc. PROCESSES FOR THE PREPARATION OF TRIAZOLO [4,5 D] PYRIMIDINE DERIVATIVES AND INTERMEDIARIES THEREOF
JP7129420B6 (ja) 2017-03-30 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１阻害剤としてのイソキノリン
AU2018244935A1 (en) 2017-03-30 2019-08-15 F. Hoffmann-La Roche Ag Naphthyridines as inhibitors of HPK1
AU2019226480B2 (en) 2018-03-02 2022-12-15 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical compounds
CN108440532A (zh) 2018-03-27 2018-08-24 上海道亦化工科技有限公司 一种苯并吡嗪化合物及其用途和发光器件
EP3802518A1 (en) 2018-05-25 2021-04-14 Silverback Therapeutics, Inc. Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
WO2019238067A1 (en) 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
WO2020103896A1 (en) 2018-11-22 2020-05-28 Beigene, Ltd. Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
CA3137916A1 (en) * 2019-05-06 2020-11-12 Ichan School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
CN112239473B (zh) 2019-07-17 2023-12-08 百济神州(北京)生物科技有限公司 作为hpk1抑制剂的三环化合物的制备方法
US20220289712A1 (en) 2019-08-21 2022-09-15 Beigene, Ltd. Aminopyrazine compounds as hpk1 inhibitor and the use thereof
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用

Also Published As

Publication number Publication date
ZA202110732B (en) 2022-09-28
US12454534B2 (en) 2025-10-28
AU2020299892A1 (en) 2022-01-27
EP3994136A1 (en) 2022-05-11
EP3994136A4 (en) 2023-06-28
CA3145751A1 (en) 2021-01-07
TW202116773A (zh) 2021-05-01
MX2022000244A (es) 2022-02-03
JP2022538019A (ja) 2022-08-31
WO2021000925A1 (en) 2021-01-07
CN114096536A (zh) 2022-02-25
CN115028639A (zh) 2022-09-09
IL289553A (en) 2022-03-01
CN115073474B (zh) 2024-10-18
CN115073474A (zh) 2022-09-20
US20220267333A1 (en) 2022-08-25
JP7579816B2 (ja) 2024-11-08
BR112022000019A2 (pt) 2022-02-22
KR20220029690A (ko) 2022-03-08
TWI848141B (zh) 2024-07-11

Similar Documents

Publication Publication Date Title
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
CR20220312A (es) Compuestos tricíclicos sustituidos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
MX2021009444A (es) Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.
CO2022002842A2 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CR20220182A (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592)
CU20210015A7 (es) COMPUESTOS DE PIRAZOLO [3.4-b] PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
BR112021011325A2 (pt) Derivados de rapamicina
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
EA201990109A1 (ru) Митохондриальные ингибиторы для лечения пролиферативных нарушений
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CO2021005738A2 (es) Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y métodos de uso
CO2021010512A2 (es) Compuesto heterociclo pentacíclico
MX2022015532A (es) Inhibidores selectivos de hdac6 y usos de los mismos.
EA202090644A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3K
AR120156A1 (es) Compuestos quiméricos de somatostatina-dopamina estables de almacenamiento y las formas salinas de estos
EA202192195A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[2,1-f][1,2,4]ТРИАЗИН-4-АМИНА В КАЧЕСТВЕ АГОНИСТА TLR7